title: Unresolved issues in hematopoietic stem cell transplantation for severe combined immunodeficiency: need for safer conditioning and reduced late effects.
abstract: In this review we discuss recent outcomes of hematopoietic cell transplantation (HCT) for patients with severe combined immunodeficiency (SCID), including survival, T- and B-cell reconstitution, and late effects, particularly those related to genotype, use of conditioning regimen, and use of alternative donors. We identify the following issues that require additional data, which can be obtained through cooperative studies: outcomes of patients with SCID who did not receive conditioning before alternative donor HCT; outcomes of patients with SCID who did not receive graft-versus-host disease prophylaxis after T cell-replete HCT; late effects of HCT for patients with SCID, including neurocognitive outcomes, growth, and development; and their relationship to genotype and use of alkylating agents for conditioning. Careful follow-up of outcomes of all newborns receiving diagnoses based on newborn screening programs for SCID is essential because data are scarce on the effects of conditioning regimens in very young patients. A consensus on the definition of T- and B-cell recovery, criteria for additional "boosts," pharmacokinetic data of chemotherapy agents used in young children, and uniformity of the use of various chemotherapy agents are needed to compare results among institutions. Finally, development of new nontoxic conditioning regimens for HCT that can be safely used in very young children is required.
authors.affiliation: Division of Allergy, Immunology, and Blood and Marrow Transplantation, Benioff Children's Hospital, University of California, San Francisco, San Francisco, CA, USA. hornb@peds.ucsf.edu
authors.forename: Biljana
authors.initials: B
authors.lastname: Horn
authors.forename: Morton J
authors.initials: MJ
authors.lastname: Cowan
mesh_terms: D046148:Donor Selection; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D016511:Severe Combined Immunodeficiency / Q000276:immunology* / Q000628:therapy*; D013997:Time Factors; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods